Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia

被引:44
作者
Sata, M
Luo, ZY
Walsh, K
机构
[1] Tufts Univ, St Elizabeths Med Ctr, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA
[2] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan
[3] Tufts Univ, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA
关键词
D O I
10.4049/jimmunol.166.11.6964
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite recent advances in immunosuppressive therapy, accelerated coronary atherosclerosis remains a major problem in the long-term survival of transplant recipients. Chronic graft vasculopathy is believed to result from recipient inflammatory responses, and it is characterized by early mononuclear cell infiltration of the transplanted vessel. Here we show that endothelial cells can be genetically modified to overexpress functional, cell-surface Fas ligand (FasL) by adenovirus-mediated gene transfer without undergoing self-destruction. In a rodent model of transplant graft vasculopathy, endothelial overexpression of FasL attenuated T cell and macrophage infiltration at 1 wk posttransplantation. These vessels also displayed reduced neointima formation at one and 2 mo posttransplantation. These results indicate that inhibition of the early inflammatory response to allografted vessels by endothelial cell-specific overexpression of FasL may have utility in the treatment of transplant arteriosclerosis.
引用
收藏
页码:6964 / 6971
页数:8
相关论文
共 63 条
[1]   Cardiac allograft vasculopathy is abrogated anti-CD8 monoclonal antibody therapy - Discussion [J].
Kirklin, JK ;
Allan, JS ;
Trinkle, JK ;
Rosengard, BR .
ANNALS OF THORACIC SURGERY, 1997, 64 (04) :1025-1025
[2]   Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts [J].
Allison, J ;
Georgiou, HM ;
Strasser, A ;
Vaux, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3943-3947
[3]   Inhibition of the alloantibody response by CD95 ligand [J].
Arai, H ;
Chan, SY ;
Bishop, DK ;
Nabel, GJ .
NATURE MEDICINE, 1997, 3 (08) :843-848
[4]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[5]  
BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19
[6]  
CALNE RY, 1989, LANCET, V2, P227
[7]   EFFECTS OF RAPAMYCIN ON GROWTH FACTOR-STIMULATED VASCULAR SMOOTH-MUSCLE CELL-DNA SYNTHESIS - INHIBITION OF BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR ACTION AND ANTAGONISM OF RAPAMYCIN BY FK506 [J].
CAO, W ;
MOHACSI, P ;
SHORTHOUSE, R ;
PRATT, R ;
MORRIS, RE .
TRANSPLANTATION, 1995, 59 (03) :390-395
[8]   Regulation of the proinflammatory effects of Fas ligand (CD95L) [J].
Chen, JJ ;
Sun, YN ;
Nabel, GJ .
SCIENCE, 1998, 282 (5394) :1714-1717
[9]   Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection [J].
Chow, LH ;
Huh, S ;
Jiang, J ;
Zhong, R ;
Pickering, JG .
CIRCULATION, 1996, 94 (12) :3079-3082
[10]  
DEMETRIS AJ, 1985, AM J PATHOL, V118, P151